Archive · 24 Jul 2026
First Ebola Vaccine Trial Begins in Oxford
Scientists at Oxford University have created a new vaccine to fight Ebola, a dangerous disease.
They tested it on a volunteer named Ed Hunt.
This vaccine was made very quickly, in just eight weeks.
The vaccine is called ChAdOx1 BDBV and uses the same technology as the Covid-19 vaccine made by AstraZeneca.
The Serum Institute of India has already made 620,000 doses of this vaccine.
The trial will check if the vaccine is safe and works well.
If it does, they plan to test it more in Uganda.
Ebola has killed more than 1,000 people in the Democratic Republic of Congo and Uganda.
The World Health Organization says the outbreak is spreading faster than ever before.
First dose of the ChAdOx1 BDBV Ebola vaccine administered to a volunteer in Oxford.
Vaccine developed in just eight weeks by Oxford University using technology similar to AstraZeneca's Covid-19 vaccine.
Serum Institute of India has stockpiled 620,000 doses of the vaccine.
Phase 1 trial will assess safety and effectiveness in 50 healthy adults.
Ebola outbreak in the DRC and Uganda has killed more than 1,000 people.
- Who
- Oxford University and the Serum Institute of India
- What
- First dose of the ChAdOx1 BDBV Ebola vaccine administered to a volunteer
- When
- Friday
- Where
- Oxford, UK
- Why
- To combat the deadly Ebola outbreak in the Democratic Republic of Congo and Uganda
Rapid Development
Potential Risks
Speed of Development
Rapid Development
The vaccine was developed rapidly in just eight weeks, showcasing extraordinary collaborative efforts.
Potential Risks
The rapid development may raise concerns about thorough testing and potential side effects.
- Vaccine Name
- ChAdOx1 BDBV
- Developed By
- Oxford University
- First Volunteer
- Ed Hunt
- Funding
- Coalition for Epidemic Preparedness Innovations (CEPI)
- Manufactured By
- Serum Institute of India
- Doses Stockpiled
- 620,000
- Outbreak Location
- Democratic Republic of Congo (DRC) and Uganda
- Death Toll
- More than 1,000